Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan

Key Points Question Is the use of Bcr-Abl tyrosine kinase inhibitors (TKIs) associated with subsequent hepatitis B virus reactivation? Findings In this nationwide nested case-control study with 733 691 individuals carrying the hepatitis B virus, Bcr-Abl TKIs were associated with overt HBV reactivation that required antiviral treatment. Women receiving Bcr-Abl TKIs had higher odds of reactivation than men. Meaning To our knowledge, this was the first population-based study that found that Bcr-Abl TKIs were associated with increased risk of HBV reactivation.